MARKET

TENX

TENX

Tenax Therapeutics Inc
NASDAQ
11.05
-1.14
-9.35%
After Hours: 11.08 +0.03 +0.27% 19:44 01/02 EST
OPEN
12.27
PREV CLOSE
12.19
HIGH
12.66
LOW
10.94
VOLUME
85.61K
TURNOVER
--
52 WEEK HIGH
14.22
52 WEEK LOW
4.630
MARKET CAP
68.99M
P/E (TTM)
-9.7857
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TENX last week (1222-1226)?
Weekly Report · 12/29/2025 10:03
Weekly Report: what happened at TENX last week (1215-1219)?
Weekly Report · 12/22/2025 10:03
Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)
TipRanks · 12/18/2025 13:36
Optimistic Outlook on Tenax Therapeutics: Buy Rating Backed by Promising Clinical Developments
TipRanks · 12/17/2025 17:35
Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF
TipRanks · 12/17/2025 16:32
Tenax Therapeutics Advances LEVEL Phase 3 Study With Enrollment Completion Expected in 2026
Reuters · 12/17/2025 15:10
Tenax Therapeutics reports result of prespecified blinded sample size assessment
TipRanks · 12/17/2025 14:26
Tenax Therapeutics Announces Prespecified Blinded Sample Size Re-Estimation Of LEVEL Demonstrated Trial Is Powered At Well Over 90% To Detect 25 Meter Change In 6MWD, Primary Endpoint
Benzinga · 12/17/2025 14:20
More
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Webull offers Tenax Therapeutics Inc stock information, including NASDAQ: TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.